

Aldeyra Therapeutics, J&J collaborate to treat Systemic Inflammatory Diseases

01 March 2018 | News

Aldeyra plans to collaborate with Janssen on the development of novel drugs designed to sequester proinflammatory aldehyde mediators



Aldeyra Therapeutics, Inc. a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases.

The company announced that it has entered into a collaborative research agreement with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Aldeyra plans to collaborate with Janssen on the development of novel drugs designed to sequester pro-inflammatory aldehyde mediators, a new class of therapeutic targets.

Aldeyra's aldehyde sequestration platform represents a novel therapeutic class, led by reproxalap, a first-in-class drug candidate that has demonstrated anti-inflammatory activity in four Phase 2 clinical trials.

The agreement is intended to advance the development of existing analogs of reproxalap for the treatment of systemic inflammatory diseases.